By Adam Clark

GlaxoSmithKline PLC (GSK.LN) said on Monday that its majority-owned ViiV Healthcare joint venture has reported positive interim results from a study of dolutegravir, a treatment for adults with both HIV and tuberculosis.

GSK said the ViiV phase IIIb study of dolutegravir showed the treatment was effective and well-tolerated in patients already receiving rifampin medication for tuberculosis.

John Pottage, chief scientific and medical officer of ViiV, said, "Tuberculosis remains the leading cause of death among people living with HIV, accounting for around one in three AIDS-related deaths. Concurrent treatment of TB and HIV remains a challenge as it is compounded by drug interactions, overlapping toxicities and immune reconstitution inflammatory syndrome."

GSK has a 78% stake in ViiV, while Shionogi & Co. Ltd. (4507.TO) and Pfizer Inc. (PFE) have minority holdings.

Shares in GlaxoSmithKline closed up 18.80 pence, or 1.5%, at 1308.80 pence on Monday.

Write to Adam Clark at adam.clark@dowjones.com

(END) Dow Jones Newswires

March 05, 2018 12:41 ET (17:41 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Gsk Charts.